YBX1 knockdown inhibits PD-L1 expression, restores functional cytotoxic CD8+ T cells, reduces MDSC and regulatory T cell infiltration, reverses chemoresistance, and reinstates anti-tumor immunity (17). Here, CD8A is linked to neoplasm.